This is an unprecedented time for innovation in life sciences — from advancements in precision medicine to artificial intelligence to advanced diagnostics, and so much more. In order to keep up with the quick pace of this evolution, WuXi AppTec’s Laboratory Testing Division (LTD) has expanded its footprint to create even more opportunities for its global partners to address unmet medical needs through the development of novel medicines.
LTD recently doubled the size of its US facility in Cranbury, New Jersey to over 115,000 square feet, expanding its open-access technology platform and integrated services and positioning the company to collaborate and innovate with partners to create disruptive technologies. Combined, LTD’s Plainsboro and new Cranbury operations will represent one of the largest laboratories in the US for preclinical and clinical drug development testing. The expansion of the capabilities in New Jersey is the latest example of LTD’s commitment to accelerate drug development around the world, and will allow its team to deliver high quality service with faster turnaround times, better leverage the resources and expertise of the local pharmaceutical and biotechnology community, and develop a stronger connection with customers.